Instem plc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Instem plc - overview
Established
1969
Location
-, -, UK
Primary Industry
Healthcare IT
About
Instem plc, based in the UK, is a healthcare software company specializing in SaaS products that optimize drug research and development processes for life science organizations globally. Founded in 1969 and headquartered in the UK, Instem plc focuses on providing innovative software solutions for drug research. The company has undergone strategic evolution to enhance its service offerings and has expanded its global reach. Andrew P Lemon serves as the CEO.
Instem plc has successfully raised GBP 5. 5 mn in its latest funding round, which was aimed at growth and innovation, bringing the total amount raised to GBP 5. 5 mn through 7 deals. CVC Capital Partners previously exited its stake in the company.
Instem specializes in delivering comprehensive Software as a Service (SaaS) products aimed at enhancing drug research and development. The company’s core offerings include In Silico & Data Insights, Study Management, Regulatory Submission, and Clinical Trial Analytics. These platforms are designed to support life science organizations by enabling data management, predictive analytics, and real-time visualization, thereby accelerating the discovery process. Instem serves a diverse client base across various sectors, including pharmaceuticals, biotechnology, clinical research organizations, and academic institutions, with a strong presence in North America, Europe, and parts of Asia.
In the most recent year of 2023, Instem reported a revenue of GBP 75,097,608 and an EBITDA of GBP -2,684,412. The company operates on a subscription-based revenue model that allows clients to access its SaaS platforms through various pricing plans tailored to organizational needs. Instem is focused on launching new products aimed at enhancing its portfolio of SaaS offerings, targeting release dates in the upcoming fiscal year. The company plans to expand its presence in emerging markets in Asia and South America by 2025, which are identified as high-growth regions for life sciences.
The recent funding of GBP 5. 5 mn will be utilized to develop these new products and support market expansion efforts.
Current Investors
Bidco
Primary Industry
Healthcare IT
Sub Industries
Bioinformatics, Healthcare IT, Medical Software
Website
www.instem.com
Verticals
HealthTech, IoT (Internet of Things)
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Instem plc - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Corporate Carve Out | Completed | Xybion Digital Inc. | - | ||||||||
| Add-on | Completed | Rockstep Solutions, Inc. | - | ||||||||
| Add-on | Completed | Strong Tower Solutions, Inc. | - | ||||||||
| Add-on, Public to Private | Completed | Instem plc | - | ||||||||
| Unspecified Exit | Completed | Instem plc | - |
Displaying 1 - 5 of 10
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.